The phase 3 AMPLIFY study provides evidence that fixed-duration acalabrutinib plus venetoclax may be a valid treatment option for fit patients with treatment-naive CLL.
Driving restrictions for blood cancer patients undergoing chimeric antigen receptor (CAR)-T cell therapy may need reconsideration, according to research presented by Rahul Banerjee, MD, FACP,…
The research could supplement patient-reported symptoms upon hospital admission for transplant procedures to predict which patients could benefit from receiving palliative care.
The FDA rejected a new drug application for sotagliflozin (Zynquista) for use as an add-on to insulin therapy for glycemic control in adults with type…
The randomized phase 3 study is evaluating amivantamab-vmjw (RYBREVANT®) plus lazertinib (LAZCLUZE™) versus osimertinib as a first-line treatment for non-small cell lung cancer.
In an interview, Blood Cancers Today speaks with Guillermo Garcia-Manero, MD, about the clinical development of ASTX727 for MDS and AML treatment.
Even temporary shift to more plant-based foods can help boost gut health
Even temporary shift to more plant-based foods can help boost gut health
AbstractBackgroundPatients with repaired tetralogy of Fallot (rTOF) have a time-dependent increased risk of ventricular tachycardia (VT). Slow conducting anatomical isthmuses (SCAIs) are the domina…
A study documented findings on vitamin D and metabolic bone disease in children requiring prolonged continuous kidney replacement therapy (CKRT).
